The TORDIA 24-week outcomes report the rates of remission/recovery, relapse, and, importantly, the characteristics of subjects that predicted outcome. To summarize, TORDIA enrolled teens ages 12—18 years (N=344) who had failed a previous trial of an SSRI and randomly assigned them to a medication switch only (another SSRI or venlafaxine) or a medication switch plus cognitive behavioral therapy (CBT) (another SSRI plus CBT or venlafaxine plus CBT). Subjects were treated for 12 weeks, and then week-12 responders were continued in their assigned arms and followed until week 24. Roughly 40% of those who failed a previous trial of an SSRI reached remission by week 24, regardless of treatment group. Responders at week 12 reached remission more quickly and at higher rates than those who responded after 12 weeks. Lower baseline depression, hopelessness, and anxiety predicted higher rates of remission, as did lower week-12 ratings of depression, hopelessness, anxiety, suicidal ideation, and family problems as well as the lack of dysthymia, anxiety, and drug use.